
Opinion|Videos|August 9, 2024
Challenges of PSA as a Diagnostic Biomarker
The key opinion leaders explore the challenges and limitations associated with using prostate-specific antigen (PSA) as a biomarker for prostate cancer detection and monitoring.
Advertisement
Episodes in this series

Video content above is prompted by the following question:
- What are some challenges or limitations in using PSA as a biomarker?
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Urology Times
1
FDA approves lutetium Lu 177 vipivotide tetraxetan for PSMA-positive mHSPC
2
Individualizing androgen pathway therapy in mCSPC
3
Testosterone deficiency: FAQs from the AUA guideline
4
Cretostimogene Grenadenorepvec: Mechanism and Rationale
5

















